Biolife Solutions

Update in progress

BLFS (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

BioLife Solutions develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry worldwide. Its offerings include HypoThermosol FRS and CryoStor media to reduce preservation-related cell damage, human platelet lysates for cell expansion, and CellSeal closed-system vials for CGT. It also provides CryoCase containers, automated processing machines, ThawSTAR thawing devices, and evo shipping containers. Direct sales and distributors; founded 1987 in Bothell, WA.

Company score

Sentiment: -0.21; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.24; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.56; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.22; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive